Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE)
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Belimumab 4 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Beimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Arm Label: Belimumab 20 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: belimumab | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 4 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Beimumab 10 mg/kg | Intervention Type: BIOLOGICAL; Name: belimumab; Assigned to Arm(s): Belimumab 20 mg/kg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
C: Arm Label: Belimumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Belimumab, Drug: Rituximab-placebo, Drug: Standard therapy (Excluding Immunosuppressants), Drug: Steroid Taper | Arm Label: Belimumab + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Belimumab, Drug: Rituximab, Drug: Standard therapy (Excluding Immunosuppressants), Drug: Steroid Taper | Arm Label: Belimumab + Standard therapy; Type: OTHER; Interventions: Drug: Belimumab, Drug: Standard therapy (Including Immunosuppressants), Drug: Steroid Taper | Intervention Type: DRUG; Name: Belimumab; Assigned to Arm(s): Belimumab + Placebo, Belimumab + Rituximab, Belimumab + Standard therapy | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Belimumab + Rituximab | Intervention Type: DRUG; Name: Rituximab-placebo; Assigned to Arm(s): Belimumab + Placebo | Intervention Type: DRUG; Name: Standard therapy (Including Immunosuppressants); Assigned to Arm(s): Belimumab + Standard therapy | Intervention Type: DRUG; Name: Standard therapy (Excluding Immunosuppressants); Assigned to Arm(s): Belimumab + Placebo, Belimumab + Rituximab | Intervention Type: DRUG; Name: Steroid Taper; Assigned to Arm(s): Belimumab + Placebo, Belimumab + Rituximab, Belimumab + Standard therapy
D: Arm Label: Placebo plus SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 4 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 4 mg/kg | Arm Label: Belimumab 10 mg/kg plus SOC; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus SOC | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 4 mg/kg; Assigned to Arm(s): Belimumab 4 mg/kg plus SOC | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus SOC

Answer: D